HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
US11458198B2 · kind B2 · utility
0Cited by
10References
19Claims
0Family size
Inventors
Key dates
| Filing date | May 27, 2020 |
| Grant date | Oct 4, 2022 |
| Priority date | — |
| Expiry date | Nov 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.